Næste

Automatisk afspilning

Camrelizumab + Apatinib for Highrisk Chemorefractory or Relapsed Gestational Trophoblastic Neoplasia

1 Visninger • 06/30/23
Del
Indlejre
administrator
administrator
Abonnenter
0

Warm Welcome to the latest OncoShorts podcast, brought to you by MedSynapse. OncoShorts covers a wide range of clinical and scientific medical content, that offers enriching insights into the World of Oncology.

In today’s podcast episode, we will discuss details of a randomized phase 2 trial, titled, Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia, featured in the November 2021 Issue of The Lancet Oncology.

Vis mere
0 Kommentarer sort Sorter efter
Facebook kommentarer

Næste

Automatisk afspilning